fda announcement tirzepatide New Medication approved by the for Chronic Weight Management! FDA shakes up weight loss

06 Confusion between routes Subcutaneous, oral, transdermal, and intranasal AOD-9604 use very different doses

When to Consider Switching or Stacking GLP-1 Medications If you've been on semaglutide alone for 6+ months and plateau despite lifestyle optimization, tirzepatide or a dual-agonist protocol may reignite results

The mental pull toward food between meals weakens

At the starting dose of 0.25 mg per week, one vial lasts 20 weeks

Factors associated with underreporting of adverse drug reactions by patients: a systematic review

Excess blood sugar as a result of insulin resistance contributes to increased fat storage plus increased cravings and appetite, further contributing to easy weight gain